KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above 50-Day Moving Average of $11.74

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $11.74 and traded as high as $11.76. KalVista Pharmaceuticals shares last traded at $11.72, with a volume of 139,487 shares changing hands.

Analyst Ratings Changes

KALV has been the topic of a number of recent research reports. HC Wainwright dropped their price target on KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. Needham & Company LLC reiterated a “buy” rating and set a $35.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, June 18th.

KalVista Pharmaceuticals Trading Up 1.8 %

The firm has a 50-day simple moving average of $11.74 and a 200-day simple moving average of $12.40. The firm has a market cap of $494.47 million, a P/E ratio of -3.72 and a beta of 0.91.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $11.53, for a total value of $86,071.45. Following the transaction, the chief executive officer now owns 224,547 shares in the company, valued at $2,589,026.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $11.53, for a total transaction of $86,071.45. Following the transaction, the chief executive officer now directly owns 224,547 shares of the company’s stock, valued at $2,589,026.91. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Benjamin L. Palleiko sold 21,959 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the sale, the chief executive officer now owns 216,387 shares of the company’s stock, valued at approximately $2,544,711.12. The disclosure for this sale can be found here. Insiders sold 37,512 shares of company stock worth $439,424 in the last three months. 12.30% of the stock is owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Zimmer Partners LP acquired a new position in shares of KalVista Pharmaceuticals during the first quarter valued at about $830,000. Price T Rowe Associates Inc. MD grew its position in KalVista Pharmaceuticals by 4.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after purchasing an additional 944 shares during the last quarter. PEAK6 Investments LLC acquired a new position in KalVista Pharmaceuticals during the 1st quarter valued at approximately $178,000. Capital World Investors purchased a new position in shares of KalVista Pharmaceuticals in the first quarter worth $17,370,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the first quarter worth $92,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.